Iodide

Iodide

SCHEMBL401190

COC(=O)C(Cc1ccc(Br)cc1)C[N+](C)(C)C.[I-]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
MME P08473 6/20 0.45
POLB P06746 1/20 0.44
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ACACB O00763 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174032 0.98 HDAC1 (0.47) HDAC1HDAC6MMEPOLBESR1
Iodide SCHEMBL397423 0.83 FOLH1 (0.44) POLBKDM4EGLAMEN1KMT2A
SCHEMBL6169888 0.82 FOLH1 (0.45) POLBKDM4EGLAMEN1KMT2A
SCHEMBL1887761 0.81 HDAC1 (0.50) HDAC1HDAC6MMEPOLBESR1
Iodide SCHEMBL8206967 0.78 LTA4H (0.60)
SCHEMBL397308 0.78 HDAC1 (0.47) HDAC1HDAC6MMEPOLBESR1
SCHEMBL6171868 0.76 LTA4H (0.61)
SCHEMBL6946548 0.76 PTPRB (0.58) HDAC1HDAC6POLBESR1ESR2
SCHEMBL4773227 0.74 KMT2A (0.53) HDAC1HDAC6POLBESR1ESR2
SCHEMBL1749708 0.74 HDAC1 (0.52) HDAC1HDAC6POLBESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101665-B2 Process for synthesis of tritiated and deuterated thiorphan and acetorphan ROCHE PALO ALTO LLC (US) 2012-01-24 US disclosed
US-20110319656-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN ROCHE PALO ALTO LLC 2011-12-29 US disclosed
WO-2009077386-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-6136842-A INHIBITION OF ENDOTHELIN-CONVERTING ENZYME HOECHST MARION ROUSSEL (FR) 2000-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319656-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN NAT1, ZRANB2, TXN HDAC1 343/4885HDAC6 806/4885MME 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.